For example, Tanox's (Houston; now part of Genentech) humanized monoclonal antibody ibalizumab (TNX-355), which blocks the human cellular CD4 receptor for HIV, is currently in phase 2 trials.

Ansun was founded in 2003 and is led by Chang, who also founded Tanox, which was acquired by Genentech. This year Ansun raised $85 million in a Series A financing led by Lilly Asia Ventures and ...